Annals of Oncology 12:S69-S73, 2001
© 2001 European Society for Medical Oncology
Symposium Article |
Ongoing trials with trastuzumab in metastatic breast cancer
The Andrew Love Cancer Centre, Cancer Services and Medical Oncology Geelong, Australia
Correspondence to: R. Bell. MD The Andrew Love Cancer Centre Cancer Services and Medical Oncology 70 Swanson Street Geelong Victoria 3220 Australia E-mail: richardb{at}barwonhealth.org.au
Following the pivotal clinical trials of trastuzumab (Herceptin), further phase II and III studies have been initiated. Preliminary results from a phase II, dose-response study of single-agent trastuzumab in 113 HER2-positive metastatic breast cancer patients without prior chemotherapy for stage IV disease have shown that the overall response rate was 23% (six complete responses and 20 partial responses), with similar results using both standard- and high-dose regimens of trastuzumab. Another phase II study of trastuzumab plus paclitaxel, both given weekly, in-63 HER2-positive and -negative patients with metastatic breast cancer produced an overall response rate of 62% in HER2-positive and 44% in HER2-negative patients. A further phase II study is underway to investigate the combination of trastuzumab plus docetaxel in 30 HER2-positive patients with metastatic breast cancer. Finally, a number of European studies are at an advanced stage of planning or are about to start patient recruitment. These include docetaxel ± trastuzumab, aromatase inhibitor ± trastuzumab, CMF (cyclophosphamide, methotrexate, 5-fluorouracil) ± trastuzumab, vinorelbine + trastuzumab, all in HER2-positive patients, and epirubicin-cyclophosphamide (EC) + trastuzumab in HER2-positive patients vs. EC alone in HER2-negative patients. The results from these trials should be available over the next one to two years.
docetaxel, epirubicin, Herceptin, metastatic breast cancer, paclitaxel, trastuzumab
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Garin, F. Le Jeune, A. Devillers, M. Cuggia, A.-S. de Lajarte-Thirouard, C. Bouriel, E. Boucher, and J.-L. Raoul Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors J. Nucl. Med., June 1, 2009; 50(6): 858 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Eddy, S. E. Kane, and G. E. Sonenshein Trastuzumab-Resistant HER2-Driven Breast Cancer Cells Are Sensitive to Epigallocatechin-3 Gallate Cancer Res., October 1, 2007; 67(19): 9018 - 9023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Campana, F. Nori, L. Piscitelli, A. M. Morselli-Labate, R. Pezzilli, R. Corinaldesi, and P. Tomassetti Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors? J. Clin. Oncol., May 20, 2007; 25(15): 1967 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bajetta, L. Catena, G. Procopio, E. Bichisao, L. Ferrari, S. Della Torre, S. De Dosso, S. Iacobelli, R. Buzzoni, L. Mariani, et al. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann. Onc., August 1, 2005; 16(8): 1374 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Van Gompel, M. Kunnimalaiyaan, K. Holen, and H. Chen ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells Mol. Cancer Ther., June 1, 2005; 4(6): 910 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Gut, June 1, 2005; 54(suppl_4): iv1 - iv16. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Z. Lin, M. A. Teitell, and G. J. Schiller The Evolution of Antibodies into Versatile Tumor-Targeting Agents Clin. Cancer Res., January 1, 2005; 11(1): 129 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pinto-de-Sousa, L. David, R. Almeida, D. Leitao, J. R. Preto, M. Seixas, and A. Pimenta c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma International Journal of Surgical Pathology, October 1, 2002; 10(4): 247 - 256. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Jahanzeb, J. E. Mortimer, F. Yunus, D. H. Irwin, J. Speyer, A. J. Koletsky, P. Klein, T. Sabir, and L. Kronish Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer Oncologist, October 1, 2002; 7(5): 410 - 417. [Abstract] [Full Text] [PDF]
|
|